Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance
← catalyst calendarNCT07769489 · readout in 112 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Triple · Other
Enrollment
100estimated
Sites
1
Country
Denmark
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-17 | estimated | When the study began enrolling |
| Primary completion | 2026-12-09 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-11 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Intervention
- Device: Syringe Pump
Primary outcomes
what the primary-completion date above is the date OFInjection pain rated on a Visual Analogue Scale (VAS)
measured 1 minute (±1 minute) from the injection initiation
Injection pain rated on a VAS
measured 9 minutes (±1minute) from the injection initiation
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed